Cel Sci Corporation (CVM)

[lightrock]

This part seems a little bit spin, in that the 10% overall survival benefit goal was to be measured as of year 3.

A small difference in year 3 mathematically will grow larger as time goes on.

So it WAS to be resounding "proof" in year 3 with a signal that big.

Now it is a question of "ok, good enough?" The effect IS "durable", continues. That counts for something.

Fair is fair, this is slightly misleading, and I am not so much complaining as being technical with this as worded. To be precise, such a statement would be about the numbers AT year 3.

From the statement at clinicaltrials.gov

Go to sections
Brief Summary:
The purpose of this study is to determine whether LI administered in combination with cyclophosphamide, indomethacin and zinc (CIZ) in a multivitamin combination prior to standard of care therapy (surgery followed by radiotherapy or concurrent radiochemotherapy) is safe and will increase the overall survival of subjects with previously untreated squamous cell carcinoma of the oral cavity or soft palate at a median of 3 years

1) Patients treated with the Multikine treatment regimen plus SOC vs. SOC alone had an overall survival benefit of 14.1% at 5 years which exceeded the pre-defined 10% overall survival benefit set out for the study population as a whole